The first line therapy for intermediate/ high risk patients with advanced renal cell carcinoma according to therapeutic program B.10
Open Access
- 19 August 2023
- journal article
- research article
- Published by Medical Education in OncoReview
- Vol. 13 (2(50)) , 48-57
Abstract
The purpose of this article is to discuss the use of therapeutic options for the first-line systemic treatment of patients with advanced renal cell carcinoma under the B.10 drug program effective in Poland as of May 2022 – with a focus on intermediate and high-risk patient populations according to the IMDC. The specific situation created by reimbursement conditions with the exclusion of regimens combined with a tyrosine kinase inhibitor and immune checkpoint inhibitors along with the marginalisation of the use of an mTOR inhibitor necessitates a choice between two-drug immunotherapy or an antiangiogenic drug in monotherapy. In this context, choosing the right treatment in the context of specific clinical situations is a challenge.Keywords
This publication has 21 references indexed in Scilit:
- Epidemiology of Renal Cell Carcinoma: 2022 UpdateEuropean Urology, 2022
- Tumors of the Urinary System and Male Genital Organs: 2022 World Health Organization Classification and MultidisciplinarityEuropean Urology, 2022
- Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinomaCancer, 2022
- ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinomaAnnals of Oncology, 2021
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trialThe Lancet Oncology, 2020
- Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trialNature Medicine, 2020
- Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trialThe Lancet Oncology, 2019
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaNature Medicine, 2018
- Cabozantinib versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007